• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.

作者信息

Grossman Joseph E, Vasudevan Divya, Joyce Cailin E, Hildago Manuel

机构信息

Agenus, Inc., Lexington, MA, USA.

Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

出版信息

Oncogene. 2021 Feb;40(8):1393-1395. doi: 10.1038/s41388-020-01611-6. Epub 2021 Jan 26.

DOI:10.1038/s41388-020-01611-6
PMID:33500548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7906900/
Abstract
摘要

相似文献

1
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.程序性死亡配体1（PD-L1）是抗程序性死亡蛋白1（PD-1）治疗的一致性生物标志物吗？Balstilimab在病毒驱动肿瘤中的模型。
Oncogene. 2021 Feb;40(8):1393-1395. doi: 10.1038/s41388-020-01611-6. Epub 2021 Jan 26.
2
Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.鉴定用于肿瘤治疗的单克隆抗体在PD-L1上pH依赖性结合的热点。
Signal Transduct Target Ther. 2020 Aug 24;5(1):158. doi: 10.1038/s41392-020-00254-z.
3
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.基于血液的肿瘤来源细胞外囊泡中的 PD-L1 分析：最佳使用抗 PD-1/PD-L1 轴抑制剂的应用。
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188463. doi: 10.1016/j.bbcan.2020.188463. Epub 2020 Nov 1.
4
Biomarkers associated with checkpoint inhibitors.与检查点抑制剂相关的生物标志物。
Ann Oncol. 2016 Jul;27(7):1199-206. doi: 10.1093/annonc/mdw181. Epub 2016 Apr 27.
5
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.PD-L1 在全身免疫中的作用：解析其对 PD-1/PD-L1 阻断免疫治疗的贡献。
Int J Mol Sci. 2020 Aug 18;21(16):5918. doi: 10.3390/ijms21165918.
6
Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies.接受基于一线抗PD-1/PD-L1疗法的癌症患者生存相关的临床和分子特征。
Biomarkers. 2020 Sep;25(6):441-448. doi: 10.1080/1354750X.2020.1794042. Epub 2020 Aug 3.
7
Predicting immunotherapy response through genomics.通过基因组学预测免疫疗法反应。
Curr Opin Genet Dev. 2021 Feb;66:1-9. doi: 10.1016/j.gde.2020.11.004. Epub 2020 Dec 8.
8
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.癌症中免疫检查点 PD-L1 和 CTLA-4 的调控机制。
J Exp Clin Cancer Res. 2021 Jun 4;40(1):184. doi: 10.1186/s13046-021-01987-7.
9
Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.抗 PD-1/PD-L1 免疫治疗预测生物标志物的研究进展与挑战：系统综述。
Cancer Lett. 2018 Feb 1;414:166-173. doi: 10.1016/j.canlet.2017.11.014. Epub 2017 Nov 16.
10
PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.PD-1/PD-L1阻断：癌症与自身免疫中免疫疗法的前景
IUBMB Life. 2021 Nov;73(11):1293-1306. doi: 10.1002/iub.2558.

引用本文的文献

1
Therapeutic Opportunities in Melanoma Through PRAME Expression.通过黑色素瘤抗原基因（PRAME）表达实现黑色素瘤的治疗机会
Biomedicines. 2025 Aug 15;13(8):1988. doi: 10.3390/biomedicines13081988.
2
MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer.微小RNA-200a调控程序性死亡受体配体1，并预测晚期非小细胞肺癌对免疫检查点抑制剂的反应。
Transl Lung Cancer Res. 2025 Jul 31;14(7):2522-2536. doi: 10.21037/tlcr-2025-117. Epub 2025 Jul 28.
3
Dual targeting of / and / immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastoma.对/和/免疫检查点的双重靶向增强了髓母细胞瘤中自然杀伤细胞介导的细胞毒性。
Neurooncol Adv. 2025 May 18;7(1):vdaf099. doi: 10.1093/noajnl/vdaf099. eCollection 2025 Jan-Dec.
4
Emerging Techniques of Translational Research in Immuno-Oncology: A Focus on Non-Small Cell Lung Cancer.免疫肿瘤学转化研究的新兴技术：聚焦非小细胞肺癌
Cancers (Basel). 2025 Jul 4;17(13):2244. doi: 10.3390/cancers17132244.
5
Chemotherapy elevates cell surface PD-L1 and MHC-I expression in apoptotic gastric cancer cells.化疗可提高凋亡胃癌细胞表面的程序性死亡受体配体1（PD-L1）和主要组织相容性复合体Ⅰ类分子（MHC-I）的表达。
Int J Immunopathol Pharmacol. 2025 Jan-Dec;39:3946320251338662. doi: 10.1177/03946320251338662. Epub 2025 May 17.
6
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab.接受阿特珠单抗治疗的转移性尿路上皮癌患者的临床和实验室参数早期动态变化可预测原发性难治性疾病。
J Immunother Cancer. 2025 May 7;13(5):e011740. doi: 10.1136/jitc-2025-011740.
7
Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.免疫检查点抑制剂在非小细胞肺癌中的利弊平衡
JAMA Oncol. 2025 May 8. doi: 10.1001/jamaoncol.2025.0985.
8
Liver Transplantation for Non-hepatocellular Carcinoma: The Role of Immune Checkpoint Inhibitors.非肝细胞癌的肝移植：免疫检查点抑制剂的作用
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102558. doi: 10.1016/j.jceh.2025.102558. Epub 2025 Mar 27.
9
Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials.PD-1/PD-L1抑制剂在晚期或复发性子宫内膜癌中的疗效和安全性：一项随机对照试验的Meta分析及试验序贯分析
Front Immunol. 2025 Jan 31;16:1521362. doi: 10.3389/fimmu.2025.1521362. eCollection 2025.
10
Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells.结直肠癌宏观环境的免疫谱分析揭示了免疫细胞的全身性功能障碍和可塑性。
Clin Transl Med. 2025 Feb;15(2):e70175. doi: 10.1002/ctm2.70175.

本文引用的文献

1
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.尼伏鲁单抗单药治疗复发性或转移性宫颈癌、阴道癌或外阴癌的安全性和疗效：来自 I/II 期 CheckMate 358 试验的结果。
J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5.
2
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.肺癌患者接受铂类药物新辅助化疗后程序性死亡配体 1 表达的变化。
J Immunother. 2019 Jul/Aug;42(6):215-220. doi: 10.1097/CJI.0000000000000275.
3
Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.谱系追踪揭示结直肠癌中 T 细胞的动态关系。
Nature. 2018 Dec;564(7735):268-272. doi: 10.1038/s41586-018-0694-x. Epub 2018 Oct 29.
4
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.帕博利珠单抗治疗复发性/转移性头颈部鳞状细胞癌的疗效和安全性：KEYNOTE-012 长期随访后的汇总分析。
Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.
5
Biomarkers for immunotherapy in bladder cancer: a moving target.膀胱癌免疫治疗的生物标志物：一个移动的目标。
J Immunother Cancer. 2017 Nov 21;5(1):94. doi: 10.1186/s40425-017-0299-1.
6
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.纳武利尤单抗免疫治疗期间的肿瘤与微环境演变
Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.
7
PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy.膀胱癌中程序性死亡受体配体1（PD-L1）的表达、转移情况及其对膀胱切除术后肿瘤学结局的影响
Oncotarget. 2017 Aug 3;8(40):66849-66864. doi: 10.18632/oncotarget.19913. eCollection 2017 Sep 15.
8
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.调节PD-L1和PD-L2表达的干扰素受体信号通路
Cell Rep. 2017 May 9;19(6):1189-1201. doi: 10.1016/j.celrep.2017.04.031.
9
Deubiquitination and Stabilization of PD-L1 by CSN5.CSN5介导的PD-L1去泛素化及稳定性维持
Cancer Cell. 2016 Dec 12;30(6):925-939. doi: 10.1016/j.ccell.2016.10.010. Epub 2016 Nov 17.
10
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.多种癌症中通过 3'-UTR 破坏导致的异常 PD-L1 表达。
Nature. 2016 Jun 16;534(7607):402-6. doi: 10.1038/nature18294. Epub 2016 May 23.